Huberman LabSupplements for Longevity & Their Efficacy | Dr. Peter Attia
CHAPTERS
- 0:00 – 14:00
Intro, Sponsors, and NAD Pathway Setup
Huberman introduces Peter Attia, outlines his credentials, and frames the episode as a deep dive into the NAD pathway and supposed longevity supplements NR, NMN, and NAD. He previews the comparison of different approaches to boosting NAD, their evidence base, and how they fit into a broader longevity framework that also includes rapamycin, metformin, and fasting.
- •Huberman positions Attia as a highly rigorous, literature-driven clinician on lifespan/healthspan.
- •Topic focus: NAD pathway (NAD, NR, NMN), delivery routes, and claims around longevity.
- •Promise to discuss what each of them actually takes and why.
- •High-level mention of rapamycin, metformin, fasting as other longevity levers.
- •Housekeeping: podcast independence from Stanford and sponsor reads (LMNT, Levels, Eight Sleep, AG1).
- 14:00 – 30:30
Attia’s Longevity Framework: Behavior, Disease-Targeting Drugs, Geroprotectors
Attia reframes Huberman’s four longevity categories into three MECE buckets: essential behaviors, exogenous molecules that target specific diseases, and geroprotective molecules that target hallmarks of aging. He emphasizes that modern longevity is fundamentally about delaying chronic diseases (cardiovascular, cancer, neurodegeneration, metabolic), and that behavior is inseparable from emotional and mental health.
- •Category 1: inescapable behaviors—eating, sleeping, moving—done in health-promoting or health-eroding ways.
- •Category 2: disease-specific drugs (e.g., metformin, SGLT2 inhibitors, GLP‑1s, statins, PCSK9 inhibitors).
- •Category 3: geroprotectors that target aging pathways/hallmarks (e.g., rapamycin for mTOR).
- •Longevity today ≈ delaying onset of chronic diseases; acute infection/trauma less dominant than 100 years ago.
- •Emotional health impacts ability to execute behaviors and affects both lifespan and healthspan.
- 30:30 – 55:00
Rapamycin as a Model Geroprotector and Its Evidence
Attia details his personal rapamycin use, dosing, and side effects, and explains why rapamycin stands out as a geroprotective drug. He highlights robust, reproducible lifespan extension across species and ongoing dog trials, contrasting this with the weaker evidence for many other interventions.
- •Attia regimen: 8 mg rapamycin weekly, typically 2 months on / 1 month off due to painful mouth ulcers.
- •Side effect (aphthous ulcers) seen in ~10% may be the only practical biomarker of exposure.
- •Mechanistic rationale: mTOR inhibition, increased autophagy, reduced senescent cells; but conviction is based more on experimental lifespan data.
- •Only caloric restriction and rapamycin extend lifespan across yeast, worms, flies, and mammals.
- •Ongoing and upcoming dog and mammal studies (e.g., Kaeberlein dog aging trial) may shift clinical enthusiasm up or down.
- •Funding and NIH priorities briefly critiqued in context of why such promising work struggles for support.
- 55:00 – 1:21:00
Sirtuins, Caloric Restriction, and the Origin of the NAD Hype
They unpack the early yeast work on sirtuins and caloric restriction that seeded the modern NAD/sirtuin longevity story. Attia shows how early assumptions that caloric restriction works via sirtuins fell apart with better experiments, and that sirtuins and CR appear to be parallel, additive, not hierarchical, pathways.
- •Yeast studies: overexpressing SIR2 in some strains extended lifespan; caloric restriction in others also did.
- •Key 2004 experiment: in a third yeast strain, CR and SIR2 overexpression both extended life additively, implying separate pathways.
- •No convincing evidence that sirtuins mediate caloric restriction’s effects on lifespan.
- •Single notable mammalian sirtuin result: SIRT6 overexpression in a transgenic mouse extended lifespan 10–15% (males only).
- •Downstream proposed sirtuin benefits: improved mitochondrial biogenesis, enhanced DNA repair, reduced SASP from senescent cells.
- •The leap from yeast/mice sirtuin data to human NAD supplementation is large and unvalidated.
- 1:21:00 – 1:33:00
Resveratrol and Failed Sirtuin Activators
Attia revisits the resveratrol saga as a cautionary tale about sirtuin activators and mouse models. Initial enthusiasm was based on a highly artificial high-fat mouse model with fatty liver–induced respiratory failure; subsequent rigorous testing, including via the ITP, failed to show lifespan benefits.
- •Resveratrol was proposed as a powerful sirtuin activator and explanation for the “French paradox.”
- •Positive result: in a bizarre model where mice on extreme high-fat diets died because fatty livers compressed their lungs, resveratrol extended life.
- •No convincing lifespan extension in normal or more relevant mouse models.
- •ITP testing (triplicate, independent labs) found no lifespan benefit from resveratrol.
- •Resveratrol doses used in studies are unrealistically high compared to what wine consumption could provide.
- 1:33:00 – 1:54:00
NAD Biology, Age-Related Changes, and Redox Potential
They dig into what NAD actually does and how it changes with age. Most NAD function is as a redox cofactor in mitochondrial energy production, not as a sirtuin substrate, and age-related NAD changes may reflect altered redox balance more than a simple deficiency that needs “topping up.”
- •Two main NAD roles: (1) cofactor in hundreds of redox reactions (NAD/NADH electron shuttling); (2) substrate for sirtuins and PARPs in DNA repair (minor fraction).
- •NAD levels are tightly regulated, akin to glucose and pH, across life stages and conditions.
- •Data suggest with age: NAD decreases modestly while NADH increases, keeping total NAD+NADH roughly constant—implying declining redox potential rather than simple NAD depletion.
- •Tissue differences: skin shows ~60% NAD decline with age; blood and brain around 15–20%.
- •Mitochondrial dysfunction and redox decline are likely more central to aging than absolute NAD concentration.
- •Huberman notes parallel work on red/near‑infrared light improving mitochondrial function in retina by reducing ROS.
- 1:54:00 – 2:18:00
The Case For and Against Boosting NAD (NR, NMN, Infusions)
They address the real-world question: does raising NAD via NR, NMN, or NAD drips do anything meaningful? Huberman shares his personal experiences with all three routes, while Attia points out that even if blood NAD rises, evidence that this matters for lifespan or healthspan is virtually absent.
- •Routes: IV NAD (painful, expensive); oral NR and NMN as precursors; oral NAD likely broken down in gut.
- •Huberman’s IV NAD experience: intense chest pressure, leg cramps, nausea during infusion; feels good afterward but similar to saline infusions.
- •Sublingual NMN gives Huberman noticeable subjective effects: faster hair/nail growth, mild energy boost, mild laxative effect.
- •Attia: whether NAD comes via NR, NMN, or IV, the practical outcome is mostly raising blood (and liver) NAD; cell-level and organ-level benefits are unclear.
- •Commercial battle (NR vs NMN) is mostly about IP and marketing; scientifically, dose-adjusted differences are likely minor.
- •FDA angle: NMN was targeted as a drug (due to a clinical trial) and flagged as non-supplement; NR retains GRAS status, but this reflects regulation and lobbying, not strong efficacy data.
- 2:18:00 – 2:34:00
What the Interventions Testing Program (ITP) Actually Shows
Attia uses the ITP to benchmark claims about NR and other compounds. The ITP’s rigorous multi-site mouse lifespan trials have identified only a handful of true hits (rapamycin, canagliflozin, acarbose, 17-α estradiol in males), and NR is not among them.
- •ITP design: genetically heterogeneous mice, three independent labs running the same protocol, lifespan as primary endpoint.
- •Very few molecules extend lifespan under ITP scrutiny; rapamycin is the standout, even when started late in life.
- •Canagliflozin (SGLT2 inhibitor) and acarbose both extended lifespan without weight loss—pointing to glycemic control as key.
- •17‑α estradiol extended lifespan only in male mice, illustrating strong sex‑specific effects in longevity interventions.
- •NR tested at high doses (500–1000 mg/kg) failed to extend lifespan or improve healthspan in ITP models.
- •Metformin also failed in the ITP, undercutting its reputation as a broad human longevity drug.
- 2:34:00 – 2:46:00
Human Trials on NR/NMN: Small Signals, Little Clinical Meaning
They dissect the main human NR and NMN trials that are often referenced in marketing. While some endpoints reach statistical significance (e.g., slight liver fat reduction in a subset, small boost in glucose disposal), the magnitude of these changes is too small to likely affect real-world outcomes.
- •NR+pterostilbene in fatty liver: three arms (placebo, standard dose, double dose); no overall change in liver fat, weight, glycemia, or inflammation.
- •Post‑hoc subset (hepatic fat <27%): single-dose group dropped from ~20% to 15% liver fat, placebo and high-dose unchanged—statistically significant, but still triple the disease threshold (≥5%).
- •NMN trial: modest, statistically significant increase in insulin-stimulated glucose disposal, but effect size similar to trivial interventions (e.g., red light before an OGTT).
- •Clear distinction between statistical significance and clinical significance: small lab changes don’t necessarily shift disease risk or lifespan.
- •Marketing tends to highlight these minor, noise-prone findings as major wins for NR/NMN; Attia characterizes the overall evidence as unimpressive.
- 2:46:00 – 3:04:00
A Possible Exception: Skin Cancer Risk and NAD Precursors
Attia highlights one area where NAD precursors may have a substantial, specific benefit: reducing incidence of non-melanoma skin cancers. He cautions that this needs replication but notes it might be a context where NAD supplementation makes sense for some individuals.
- •One study reported 60–80% reduction in basal cell and squamous cell carcinoma incidence with NAD-precursor use.
- •No effect on melanoma, the deadliest skin cancer.
- •Given skin’s large age‑related NAD decline, it’s plausible NAD augmentation could meaningfully affect skin cell DNA repair and UV damage handling.
- •Could be rational for high-risk persons (light skin, heavy sun exposure, outdoor workers) if replicated.
- •Even here, Attia wants confirmation before recommending NR/NMN primarily for this purpose.
- 3:04:00 – 3:24:00
Biological Age Tests, Radiation Anxiety, and Perspective
They critique current biological age tests and address common fears about radiation from flights and scanners. Attia argues that most clocks are noisy and unvalidated for practical decisions, and that everyday radiation exposures are well below dangerous levels, helping contextualize real vs perceived risks.
- •Key question for any biological age test: does it predict remaining lifespan better than chronological age?
- •Current clocks (biomarker composites, epigenetic) have high noise and weak standardization; a 60‑year‑old with “bio-age 35” has no evidence-based guarantee of 60+ more years.
- •Ideal validation (e.g., in mice) comparing biological vs chronological age for survival prediction has largely not been done.
- •Epigenetic assays used commercially often don’t truly sequence methylation base-by-base; outputs are approximate.
- •Radiation context: typical background ≈1 mSv/year at sea level, ≈2 mSv/year at altitude; medical CT ~3–15 mSv; occupational exposures can be much higher without clear cancer excess.
- •Airport scanners and normal flight exposure are not large longevity threats compared to lifestyle factors.
- 3:24:00 – 3:40:00
The Critical Role of Midlife: Muscle, Power, and Reserve
They shift from molecules to midlife strategy, arguing that the 50s–70s are decisive for building physiological reserve. Strength, muscle mass, and power are much easier to build and maintain now than in late life, making consistent training in this window central to healthspan and independence in older age.
- •Attia: 50s–70s is the key window where aging becomes apparent but adaptation capacity remains high.
- •Muscle mass, strength, and especially power (e.g., vertical jump) decline with age; power declines first and fastest.
- •Compounding: staying in the game continuously matters; prolonged inactivity in midlife is costly and hard to reverse.
- •Late-life muscle gain is possible but far harder; better to overbuild reserve now.
- •Huberman notes timing of exercise—especially early morning workouts—can dramatically change subjective energy across the day, an under-discussed aspect of adherence.
- 3:40:00 – 3:55:00
Energy with Age, Kids’ Spontaneous Activity, and Limits of Supplements
They reflect on why children have such boundless, spontaneous energy while adults become more conservative with movement and energy expenditure. They acknowledge the mystery of age-related energy declines, speculate about mitochondrial roles, and reiterate that no supplement currently rivals the impact of sleep, training, and diet on day-to-day vigor.
- •Observation: children spontaneously sprint and move constantly; adults rarely do without a deliberate reason.
- •Aging brings reduced resilience to sleep loss and stress; recovery demands increase.
- •Possible links to mitochondrial function, NAD, and redox, but no definitive mechanistic explanation for subjective energy decline.
- •Huberman’s anecdote: early-morning workouts (<9 a.m.) give full-day energy; mid-late morning workouts often cause afternoon fatigue.
- •Attia: no pill, including rapamycin, comes close to the energy impact of getting sleep, nutrition, and exercise right.
- 3:55:00 – 4:25:00
What Huberman and Attia Actually Take (and Why)
Both disclose their personal supplement and drug regimens, providing practical context to their theoretical positions. Attia focuses on evidence-backed disease-modifying drugs and a few plausible geroprotectors; Huberman emphasizes foundational micronutrient coverage, fish oil, creatine, and a small number of compounds with subjective or mechanistic appeal.
- •Attia’s regimen includes: PCSK9 inhibitor, bempedoic acid, SGLT2 inhibitor (disease-modifying); rapamycin (geroprotector); EPA/DHA; theracurmin; vitamin D3; methylfolate and methyl B12; multiple forms of magnesium (L‑threonate, chloride, oxide); ashwagandha for sleep; electrolytes (LMNT); creatine; and specific probiotics (Pendulum products with anaerobic strains like Akkermansia).
- •Huberman’s regimen includes: AG1 daily; fish oil to reach ≥1 g EPA/day; vitamin D3 (3–7k IU/day based on labs); methyl B12; tongkat ali (to lower SHBG and slightly raise free T); green tea/yerba mate and coffee; NMN/NR intermittently; LMNT for electrolytes; 10 g creatine monohydrate; magnesium L‑threonate, apigenin, theanine, sometimes inositol for sleep; whey protein.
- •Huberman has experimented with nicotine gum and alpha-GPC as performance aids but is cautious about dependency and other risks.
- •Both emphasize they consider these supplements as optional augmentations or insurance policies, not core longevity tools.
- •Consensus: not taking NR, NMN, or NAD with any conviction for lifespan; if they run out, neither feels compelled to replace them urgently.
- 4:25:00
Final Verdict on NAD Pathway Supplements and Closing Thoughts
They converge on a clear stance: current data do not support using NR, NMN, or NAD infusions to extend human lifespan, and any healthspan benefits appear modest and context-specific. They stress intellectual honesty, willingness to change views with new data, and a strong recommendation to prioritize behaviors over boutique interventions.
- •On NAD-pathway supplements for longevity: both say their answer is no based on current evidence.
- •Attia explicitly does not take NR/NMN and has “no foreseeable plan” to do so unless strong new data emerge.
- •He highlights the importance of showing conviction via one’s portfolio of actions, not just speculation.
- •Huberman reiterates that exercise, sleep, nutrition, and emotional health far outweigh supplement choices.
- •They close with appreciation for rigorous science, willingness to update beliefs, and direction to Huberman’s other content and newsletter for practical protocols.
